AAPL343.82-3.28 (-0.95%) ▼|ABBV286.53+0.14 (+0.05%) ▲|ABT102.67-0.43 (-0.42%) ▼|ACN243.97+8.81 (+3.74%) ▲|ADBE249.76+1.40 (+0.56%) ▲|AMAT416.00+20.07 (+5.07%) ▲|AMD578.44+18.18 (+3.24%) ▲|AMGN451.83+3.88 (+0.87%) ▲|AMT183.75-0.08 (-0.04%) ▼|AMZN254.60+1.50 (+0.59%) ▲|AVGO351.81+9.48 (+2.77%) ▲|AXP318.26+5.35 (+1.71%) ▲|BA167.14-1.04 (-0.62%) ▼|BAC50.85+0.17 (+0.34%) ▲|BKNG147.94-2.20 (-1.47%) ▼|BLK1,157.88+21.83 (+1.92%) ▲|BMY60.57-0.98 (-1.59%) ▼|BNY148.59+1.01 (+0.68%) ▲|BRK-B540.34-2.65 (-0.49%) ▼|C124.11+1.42 (+1.16%) ▲|CAT713.38+0.07 (+0.01%) ▲|CL91.69-0.48 (-0.52%) ▼|CMCSA21.57-0.27 (-1.24%) ▼|COF204.88+1.44 (+0.71%) ▲|COP149.06+1.10 (+0.74%) ▲|COST982.73-9.40 (-0.95%) ▼|CRM242.11+1.22 (+0.51%) ▲|CSCO110.29-1.09 (-0.98%) ▼|CVS89.95-1.18 (-1.29%) ▼|CVX229.29+1.06 (+0.46%) ▲|DE640.67+1.09 (+0.17%) ▲|DHR234.07+2.07 (+0.89%) ▲|DIS109.07-1.16 (-1.05%) ▼|DUK123.57-1.23 (-0.99%) ▼|EMR167.71+1.44 (+0.87%) ▲|FDX304.58-2.52 (-0.82%) ▼|GD354.35-0.54 (-0.15%) ▼|GE301.13+3.47 (+1.17%) ▲|GEV878.03-17.05 (-1.90%) ▼|GILD159.20+0.12 (+0.08%) ▲|GM82.48+1.94 (+2.41%) ▲|GOOG321.89+5.06 (+1.60%) ▲|GOOGL324.89+4.31 (+1.34%) ▲|GS925.17+13.40 (+1.47%) ▲|HD317.56-0.94 (-0.30%) ▼|HON219.26+0.45 (+0.21%) ▲|IBM253.22+2.97 (+1.19%) ▲|INTC95.53+1.79 (+1.91%) ▲|INTU328.19-0.26 (-0.08%) ▼|ISRG444.18-1.70 (-0.38%) ▼|JNJ271.04+2.31 (+0.86%) ▲|JPM339.30+3.51 (+1.05%) ▲|KO91.73+0.55 (+0.60%) ▲|LIN508.16-0.49 (-0.10%) ▼|LLY1,288.30+6.39 (+0.50%) ▲|LMT629.75+6.76 (+1.09%) ▲|LOW198.40+0.22 (+0.11%) ▲|LRCX253.82+12.97 (+5.39%) ▲|MA610.31+0.46 (+0.08%) ▲|MCD250.50+1.03 (+0.41%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.78+0.83 (+0.88%) ▲|META612.49-7.70 (-1.24%) ▼|MMM172.80+1.22 (+0.71%) ▲|MO72.99-0.50 (-0.68%) ▼|MRK140.93-0.89 (-0.63%) ▼|MS190.13+3.22 (+1.72%) ▲|MSFT531.01-0.32 (-0.06%) ▼|MU983.23+54.47 (+5.86%) ▲|NEE81.02-1.40 (-1.70%) ▼|NFLX61.99-0.53 (-0.85%) ▼|NKE37.15-0.41 (-1.09%) ▼|NOW150.13-4.65 (-3.00%) ▼|NVDA215.38-2.56 (-1.17%) ▼|ORCL144.54+14.01 (+10.73%) ▲|PEP132.63-0.87 (-0.65%) ▼|PFE29.45-0.35 (-1.17%) ▼|PG158.26-0.97 (-0.61%) ▼|PLTR196.81-1.92 (-0.97%) ▼|PM202.64+0.02 (+0.01%) ▲|QCOM182.97-1.20 (-0.65%) ▼|RTX195.84+1.24 (+0.64%) ▲|SBUX103.20+0.16 (+0.16%) ▲|SCHW88.76-0.54 (-0.60%) ▼|SO91.52-1.13 (-1.22%) ▼|SPG211.24-1.04 (-0.49%) ▼|T20.70-0.24 (-1.15%) ▼|TMO704.15+11.13 (+1.61%) ▲|TMUS148.08+1.25 (+0.85%) ▲|TSLA404.22-3.24 (-0.80%) ▼|TXN309.83+0.92 (+0.30%) ▲|UBER65.27-0.51 (-0.78%) ▼|UNH407.10-3.29 (-0.80%) ▼|UNP297.80-2.08 (-0.69%) ▼|UPS105.62-0.47 (-0.44%) ▼|USB59.60-0.14 (-0.23%) ▼|V400.60-1.26 (-0.31%) ▼|VZ43.18-0.75 (-1.71%) ▼|WFC83.67+1.01 (+1.22%) ▲|WMT118.77-0.55 (-0.46%) ▼|XOM182.02+2.11 (+1.17%) ▲|AAPL343.82-3.28 (-0.95%) ▼|ABBV286.53+0.14 (+0.05%) ▲|ABT102.67-0.43 (-0.42%) ▼|ACN243.97+8.81 (+3.74%) ▲|ADBE249.76+1.40 (+0.56%) ▲|AMAT416.00+20.07 (+5.07%) ▲|AMD578.44+18.18 (+3.24%) ▲|AMGN451.83+3.88 (+0.87%) ▲|AMT183.75-0.08 (-0.04%) ▼|AMZN254.60+1.50 (+0.59%) ▲|AVGO351.81+9.48 (+2.77%) ▲|AXP318.26+5.35 (+1.71%) ▲|BA167.14-1.04 (-0.62%) ▼|BAC50.85+0.17 (+0.34%) ▲|BKNG147.94-2.20 (-1.47%) ▼|BLK1,157.88+21.83 (+1.92%) ▲|BMY60.57-0.98 (-1.59%) ▼|BNY148.59+1.01 (+0.68%) ▲|BRK-B540.34-2.65 (-0.49%) ▼|C124.11+1.42 (+1.16%) ▲|CAT713.38+0.07 (+0.01%) ▲|CL91.69-0.48 (-0.52%) ▼|CMCSA21.57-0.27 (-1.24%) ▼|COF204.88+1.44 (+0.71%) ▲|COP149.06+1.10 (+0.74%) ▲|COST982.73-9.40 (-0.95%) ▼|CRM242.11+1.22 (+0.51%) ▲|CSCO110.29-1.09 (-0.98%) ▼|CVS89.95-1.18 (-1.29%) ▼|CVX229.29+1.06 (+0.46%) ▲|DE640.67+1.09 (+0.17%) ▲|DHR234.07+2.07 (+0.89%) ▲|DIS109.07-1.16 (-1.05%) ▼|DUK123.57-1.23 (-0.99%) ▼|EMR167.71+1.44 (+0.87%) ▲|FDX304.58-2.52 (-0.82%) ▼|GD354.35-0.54 (-0.15%) ▼|GE301.13+3.47 (+1.17%) ▲|GEV878.03-17.05 (-1.90%) ▼|GILD159.20+0.12 (+0.08%) ▲|GM82.48+1.94 (+2.41%) ▲|GOOG321.89+5.06 (+1.60%) ▲|GOOGL324.89+4.31 (+1.34%) ▲|GS925.17+13.40 (+1.47%) ▲|HD317.56-0.94 (-0.30%) ▼|HON219.26+0.45 (+0.21%) ▲|IBM253.22+2.97 (+1.19%) ▲|INTC95.53+1.79 (+1.91%) ▲|INTU328.19-0.26 (-0.08%) ▼|ISRG444.18-1.70 (-0.38%) ▼|JNJ271.04+2.31 (+0.86%) ▲|JPM339.30+3.51 (+1.05%) ▲|KO91.73+0.55 (+0.60%) ▲|LIN508.16-0.49 (-0.10%) ▼|LLY1,288.30+6.39 (+0.50%) ▲|LMT629.75+6.76 (+1.09%) ▲|LOW198.40+0.22 (+0.11%) ▲|LRCX253.82+12.97 (+5.39%) ▲|MA610.31+0.46 (+0.08%) ▲|MCD250.50+1.03 (+0.41%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.78+0.83 (+0.88%) ▲|META612.49-7.70 (-1.24%) ▼|MMM172.80+1.22 (+0.71%) ▲|MO72.99-0.50 (-0.68%) ▼|MRK140.93-0.89 (-0.63%) ▼|MS190.13+3.22 (+1.72%) ▲|MSFT531.01-0.32 (-0.06%) ▼|MU983.23+54.47 (+5.86%) ▲|NEE81.02-1.40 (-1.70%) ▼|NFLX61.99-0.53 (-0.85%) ▼|NKE37.15-0.41 (-1.09%) ▼|NOW150.13-4.65 (-3.00%) ▼|NVDA215.38-2.56 (-1.17%) ▼|ORCL144.54+14.01 (+10.73%) ▲|PEP132.63-0.87 (-0.65%) ▼|PFE29.45-0.35 (-1.17%) ▼|PG158.26-0.97 (-0.61%) ▼|PLTR196.81-1.92 (-0.97%) ▼|PM202.64+0.02 (+0.01%) ▲|QCOM182.97-1.20 (-0.65%) ▼|RTX195.84+1.24 (+0.64%) ▲|SBUX103.20+0.16 (+0.16%) ▲|SCHW88.76-0.54 (-0.60%) ▼|SO91.52-1.13 (-1.22%) ▼|SPG211.24-1.04 (-0.49%) ▼|T20.70-0.24 (-1.15%) ▼|TMO704.15+11.13 (+1.61%) ▲|TMUS148.08+1.25 (+0.85%) ▲|TSLA404.22-3.24 (-0.80%) ▼|TXN309.83+0.92 (+0.30%) ▲|UBER65.27-0.51 (-0.78%) ▼|UNH407.10-3.29 (-0.80%) ▼|UNP297.80-2.08 (-0.69%) ▼|UPS105.62-0.47 (-0.44%) ▼|USB59.60-0.14 (-0.23%) ▼|V400.60-1.26 (-0.31%) ▼|VZ43.18-0.75 (-1.71%) ▼|WFC83.67+1.01 (+1.22%) ▲|WMT118.77-0.55 (-0.46%) ▼|XOM182.02+2.11 (+1.17%) ▲|
16.6 C
New York
Wednesday, October 28, 2026

Tag: pharmaceutical

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...

Autoket Rebrands As Supply Veins, Relaunching As An AI-Powered Communications Platform to Revolutionize B2B Procurement Across All Industries

The Supply Veins Co-Founder and CEO is a PenFed Foundation for Military Heroes Veteran Entrepreneur Program Alumnus Multimedia: VIDEO LINK MIAMI, Aug. 1, 2025 /PRNewswire/ -- Autoket,...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

Jewellok Unveils Cutting-Edge Specialty Gas Changeover Manifolds to Revolutionize Industrial and Medical Gas Delivery

Jewellok is a specialty gas automatic changeover manifold manufacturer and supplier, manufacturing semi-automatic and automatic stainless steel high-purity oxygen, nitrogen, helium, and argon gas...

Suppositories Market Worth $2.05 billion by 2030 with 4.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The global Suppositories Market, valued at US$1.56 billion in 2024 stood at US$1.63 billion in 2025 and...

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911,...

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data  PITTSBURGH, Aug. 1, 2025 /PRNewswire/...

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the...

NeuroSense Provides Business Update and Progress for the First Half of 2025

CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided...

Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader

Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun...

Chromatography Resin Market worth $4.94 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic Media), Technique ((Ion Exchange (Cation and Anion), Affinity...

Chromatography Resin Market worth $4.94 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic Media), Technique ((Ion Exchange (Cation and Anion), Affinity...

Atombeat and BioDuro Announce Strategic Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery

SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a...

BrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the second quarter ended June 30, 2025, and increased Revenue and Adjusted EBITDA1 guidance.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical